(-0.56%) 5 043.17 points
(-0.94%) 38 099 points
(-0.82%) 15 583 points
(0.13%) $82.92
(-1.21%) $1.633
(0.16%) $2 342.20
(0.12%) $27.38
(0.84%) $923.45
(-0.33%) $0.931
(-0.17%) $10.96
(-0.46%) $0.799
(-0.05%) $92.27
@ $137.57
Issued: 25 Apr 2024 @ 11:21
Return: -0.41%
Previous signal: Apr 25 - 10:39
Previous signal:
Return: 0.38 %
Live Chart Being Loaded With Signals
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas...
Stats | |
---|---|
Today's Volume | 301 734 |
Average Volume | 885 569 |
Market Cap | 13.63B |
EPS | $0 ( 2024-02-07 ) |
Next earnings date | ( $1.040 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 55.47 |
ATR14 | $3.31 (2.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Benevich Eric | Buy | 12 587 | Common Stock |
2024-04-15 | Benevich Eric | Buy | 7 231 | Common Stock |
2024-04-15 | Benevich Eric | Sell | 12 587 | Common Stock |
2024-04-15 | Benevich Eric | Sell | 7 231 | Non-Qualified Stock Option |
2024-04-15 | Benevich Eric | Sell | 12 587 | Non-Qualified Stock Option |
INSIDER POWER |
---|
21.05 |
Last 100 transactions |
Buy: 793 011 | Sell: 504 436 |
Volume Correlation
Neurocrine Biosciences Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Neurocrine Biosciences Correlation - Currency/Commodity
Neurocrine Biosciences Financials
Annual | 2023 |
Revenue: | $1.89B |
Gross Profit: | $1.85B (97.90 %) |
EPS: | $2.56 |
Q4 | 2023 |
Revenue: | $515.20M |
Gross Profit: | $506.70M (98.35 %) |
EPS: | $1.500 |
Q3 | 2023 |
Revenue: | $498.80M |
Gross Profit: | $487.60M (97.75 %) |
EPS: | $0.850 |
Q2 | 2023 |
Revenue: | $452.70M |
Gross Profit: | $441.20M (97.46 %) |
EPS: | $0.980 |
Financial Reports:
No articles found.
Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators